Compare LW & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | MMED |
|---|---|---|
| Founded | 1950 | 1983 |
| Country | United States | United States |
| Employees | 10000 | 2800 |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.6B |
| IPO Year | 2016 | 2025 |
| Metric | LW | MMED |
|---|---|---|
| Price | $43.68 | $20.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $44.14 | $22.56 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 04-01-2026 | 06-03-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | N/A | ★ $3,102,000,000.00 |
| Revenue This Year | $4.26 | $15.99 |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $37.62 | $10.65 |
| 52 Week High | $67.07 | $24.43 |
| Indicator | LW | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 25.73 | 41.73 |
| Support Level | $42.96 | $10.68 |
| Resistance Level | $44.57 | $20.88 |
| Average True Range (ATR) | 1.38 | 0.93 |
| MACD | -0.48 | -0.41 |
| Stochastic Oscillator | 1.39 | 10.17 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.